Centauri Therapeutics
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Alderley Park Nether Alderley, Alderley ...Phone Number
+44 1625238620Website
www.centauritherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Centauri Therapeutics
Centauri Therapeutics is a UK-based immunotherapy company leveraging its proprietary Alphamer® platform to redirect the immune system against drug-resistant infections and other high-unmet-need diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Centauri Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Centauri Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Centauri Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Centauri Therapeutics is spiking on competitors!
Centauri Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Centauri Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Centauri Therapeutics
Website visits: Recent activity has been detected on your website
Click to see if Centauri Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Centauri Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Centauri Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Centauri Therapeutics
Compare insights from companies similar to Centauri Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Centauri Therapeutics
<$5M
1-10
Private
$43.5M
2014
N/A
Company Profile Activity
Activity Insights
Centauri Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Centauri Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Centauri Therapeutics.
Centauri Therapeutics financials insights
Gather financial insights about Centauri Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Unspecified
$4.3M
2017
Angel/Seed
$1.5M
2022
Series A
$32.6M
2025
Unspecified
$5.1M
Centauri Therapeutics Tech Stack
A closer look at the technologies used by Centauri Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Board of Directors
New Hire
Executive Move
New Hire
Executive Move
Centauri Therapeutics News & Media
Centauri gets $5.1M from CARB-X to advance ABX-01 to human trials
UK-based Centauri Therapeutics, an immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic areas, has secured an additional $5.1 million in funding f...Centauri Therapeutics Selects First Clinical Candidate, for Immunotherapeutic Treatment of Gram-negative Bacterial Infections
LONDON--(BUSINESS WIRE)--Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the selection of its first clinical candidate in the ABX-01 programme. Based on the Company’s Alphamer® platform, the compound is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. This drug canCentauri Therapeutics Strengthens Senior Leadership Team With Three Key Appointments
LONDON--(BUSINESS WIRE)--Centauri Therapeutics Limited (Centauri), an immunotherapy company focused on the treatment of infectious diseases, today announced three senior appointments: Dr Jennifer Schneider as Chief Executive Officer (CEO), Dr Helen Bright as Vice President (VP) of Research & Development (R&D), and Professor David Roblin FRCP FMedSci as Chair of the Board of Directors. The appointments bring extensive expertise in the discovery, development and commercialisation of medicCentauri Therapeutics' $32 Million Series A Investment - Global Legal Chronicle
Goodwin advised BIVF, Novo and Evotec on the deal. Boehringer Ingelheim Venture Fund GmbH (“BIVF”), Novo Holdings REPAIR Impact Fund (“Novo”) and Evotec SE (“Evotec”) led …
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Centauri Therapeutics
Sign Up For FreeTo access detailed company insights
Centauri Therapeutics is a UK-based immunotherapy company leveraging its proprietary Alphamer® platform to redirect the immune system against drug-resistant infections and other high-unmet-need diseases.... Read More
